OC-01, a varenicline nasal spray for the treatment of ocular surface diseases, was safe and well tolerated in a phase 1 study, Oyster Point Pharma announced in a press release.
The open-label, single-center, randomized, two-way crossover ZEN study assessed the relative bioavailability of OC-01 at its highest intended clinical strength (varenicline 1.2 mg/mL in a 50 µL nasal spray) compared with Chantix (varenicline 1 mg oral tablet, Pfizer) in 22 healthy volunteers.
Topline results of the study found OC-01 nasal spray to be safe and well tolerated with no serious (Read more...)
Uncategorized